Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

29.76
+1.374.83%
Post-market: 29.810.0542+0.18%19:56 EDT
Volume:2.46M
Turnover:72.85M
Market Cap:3.07B
PE:-35.53
High:30.50
Open:28.74
Low:28.61
Close:28.39
52wk High:38.26
52wk Low:16.02
Shares:103.29M
Float Shares:91.60M
Volume Ratio:1.31
T/O Rate:2.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8376
EPS(LYR):-0.8100
ROE:-8.18%
ROA:-17.01%
PB:2.88
PE(LYR):-36.74

Loading ...

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)

TIPRANKS
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

Evercore ISI Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

Analysts Offer Insights on Healthcare Companies: Waters (WAT), Beam Therapeutics (BEAM) and Green Thumb Industries (OtherGTBIF)

TIPRANKS
·
Aug 05

Clear Street Remains a Buy on Beam Therapeutics (BEAM)

TIPRANKS
·
Aug 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 05

Beam Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 04

Earnings Flash (BEAM) Beam Therapeutics Posts Q2 Loss $1.18 a Share, vs. FactSet Est of $1.11 Loss

MT Newswires Live
·
Aug 04

Beam Therapeutics Q2 Operating Expenses USD 127.043 Million

THOMSON REUTERS
·
Aug 04

Beam Therapeutics Q2 License and Collaboration Revenue USD 490 Thousand

THOMSON REUTERS
·
Aug 04

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of Beam-302 Trial in Alpha-1 Antitrypsin Deficiency (Aatd)

THOMSON REUTERS
·
Aug 04

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire
·
Aug 04

Scribe's Genetic Editing Aims to Prevent Heart Attacks

Dow Jones
·
Jul 30

Beam Therapeutics Announces Press Release Availability

Reuters
·
Jul 23

Beam Therapeutics (BEAM) Following Ark Invest Interest And Clinical Milestones Looks Undervalued

Simply Wall St.
·
Jul 23

TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647

TIPRANKS
·
Jul 09

Resolution in favor of Prime has limited impact to Beam, says BofA

TIPRANKS
·
Jul 08

Prime Medicine Wins Arbitration with Beam over AATD Therapy PM647

Reuters
·
Jul 08

Ambarella, Beam, United Micro, Hyperscale Data, Atai Beckley Shocking Insider Moves

TIPRANKS
·
Jul 04

Beam Therapeutics CEO John M. Evans Disposes of 49,000 Common Shares Worth $1.72 Million

Reuters
·
Jul 02